Tigenix NV, of Leuven, Belgium, said the first patient was enrolled and treated in its phase Ib/IIa trial for Cx611 (SEPCELL) in the treatment of severe sepsis in community-acquired pneumonia. Cx611 is an intravenously administered product of allogeneic expanded adipose-derived stem cells.